ArticleCureus2026
Pathophysiologic Study of the Changes of Blood Flow in Portal Vein and Hepatic Artery and the Role of Administration of Regadenoson in Post-hepatectomy Liver Failure.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backround Posthepatectomy liver failure syndrome is a well-described complication after extended hepatectomies, which contributes significantly to the perioperative morbidity and mortality of the patient. The major pathophysiological basis of this syndrome is the hepatic arterial buffer response (HABR), which reflects the hemodynamic changes that occur in the liver after a hepatectomy. As the portal vein is unable to adjust blood flow to the diminished hepatic parenchyma, the liver establishes a unique mechanism that leads to a decrease in the flow of hepatic artery via vasoconstriction. There are surgical techniques that are already applied to reverse this phenomenon, but they are still considered risky, as they carry high perioperative mortality. On the other hand, pharmacological modulation of the hepatic vasculature can reverse the HABR phenomenon and contribute to the treatment of post-hepatectomy liver failure (PHLF) syndrome. In our experimental research, we studied the administration of regadenoson, an A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.